Polylactide-co-glycolide nanoparticles for controlled delivery of anticancer agents

The effectiveness of anticancer agents may be hindered by low solubility in water, poor permeability, and high efflux from cells. Nanomaterials have been used to enable drug delivery with lower toxicity to healthy cells and enhanced drug delivery to tumor cells. Different nanoparticles have been dev...

Full description

Saved in:
Bibliographic Details
Published in:International journal of nanomedicine 2011-01, Vol.6 (default), p.877-895
Main Authors: Dinarvand, R, Sepehri, N, Manoochehri, S, Rouhani, H, Atyabi, F
Format: Article
Language:English
Subjects:
anticancer agents
Antineoplastic Agents - administration & dosage
Antineoplastic Agents - chemistry
Delayed-Action Preparations
Drug Delivery Systems
Lactic Acid - administration & dosage
Lactic Acid - chemistry
Nanotechnology
Polyglycolic Acid - administration & dosage
Polyglycolic Acid - chemistry
Polylactic Acid-Polyglycolic Acid Copolymer
polymeric nanocarriers
Review
surface modification
targeting
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The effectiveness of anticancer agents may be hindered by low solubility in water, poor permeability, and high efflux from cells. Nanomaterials have been used to enable drug delivery with lower toxicity to healthy cells and enhanced drug delivery to tumor cells. Different nanoparticles have been developed using different polymers with or without surface modification to target tumor cells both passively and/or actively. Polylactide-co-glycolide (PLGA), a biodegradable polyester approved for human use, has been used extensively. Here we report on recent developments concerning PLGA nanoparticles prepared for cancer treatment. We review the methods used for the preparation and characterization of PLGA nanoparticles and their applications in the delivery of a number of active agents. Increasing experience in the field of preparation, characterization, and in vivo application of PLGA nanoparticles has provided the necessary momentum for promising future use of these agents in cancer treatment, with higher efficacy and fewer side effects.
ISSN:1178-2013
1176-9114
1178-2013
DOI:10.2147/ijn.s18905